Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Lyrica® CR (pregabalin extended-release) - New formulation approved

    by
    • Optum Workers' Comp
    | Oct 24, 2017
    Tag Icon
    Diabetes, FDA
    Pfizer Inc. recently announced the approval of Lyrica CR (pregabalin) extended-release tablets by the U.S. Food and Drug Administration (FDA). Lyrica CR has been approved for once-daily therapy for the treatment of neuropathic (nerve) pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN), known as nerve pain caused by shingles.


  • FDA approves Vosevi™ for the treatment of chronic Hepatitis C virus infection

    by
    • Optum Workers' Comp
    | Jul 20, 2017
    Tag Icon
    Medication Plans, FDA
    The U.S. Food and Drug Administration (FDA) has approved a new fixed-dose, combination medication Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.


  • Opioid analgesics have a place in therapy; knowing when and how to use is key

    by
    • Optum Workers' Comp
    | Jul 11, 2017
    Tag Icon
    Chronic Pain, Pain Management, Opioids, FDA
    The recent agreement between the U.S. Food and Drug Administration (FDA) and Endo Pharmaceuticals to have Opana® ER removed from the U.S. market highlights the ongoing need for awareness on the safety of opioid analgesics and a better understanding of how the medication can affect the major body systems. While this decision resulted from research determining the benefits of using reformulated Opana ER no longer outweigh its risks, the question of whether or not opioid analgesics should continue to have a place in medication therapy remains.


  • Kentucky takes stance on gabapentin to help reduce risk to public health

    by
    • Optum Workers' Comp
    | Jul 07, 2017
    Tag Icon
    FDA, DEA, Abuse Deterrent
    Kentucky has recently classified all gabapentin products as a Schedule V Controlled Substance to help reduce the risk to public health. This new state regulation, effective July 1, 2017, differs from federal regulations in that the state of Kentucky recognizes the abuse potential of gabapentin.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.